Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). BRAIN Biotech AG's share price for the quarter that ended in Mar. 2026 was €2.39. BRAIN Biotech AG's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 21.85 Mil. Therefore, BRAIN Biotech AG's market cap for the quarter that ended in Mar. 2026 was €52.21 Mil.
BRAIN Biotech AG's quarterly market cap
increased
from Sep. 2025 (€47.41 Mil) to Dec. 2025 (€52.65 Mil) but then
declined
from Dec. 2025 (€52.65 Mil) to Mar. 2026 (€52.21 Mil).
BRAIN Biotech AG's annual market cap
declined
from Sep. 2023 (€90.88 Mil) to Sep. 2024 (€46.75 Mil) but then
increased
from Sep. 2024 (€46.75 Mil) to Sep. 2025 (€47.41 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. BRAIN Biotech AG's Enterprise Value for Today is €61.27 Mil.
BRAIN Biotech AG (HAM:BNN) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
BRAIN Biotech AG Market Cap Related Terms
BRAIN Biotech AG Market Cap Historical Data
* Premium members only.
The historical data trend for BRAIN Biotech AG's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Specialty Chemicals subindustry, BRAIN Biotech AG's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BRAIN Biotech AG Market Cap vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, BRAIN Biotech AG's Market Cap distribution charts can be found below:
* The bar in red indicates where BRAIN Biotech AG's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
BRAIN Biotech AG's Market Cap for the fiscal year that ended in Sep. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BRAIN Biotech AG (HAM:BNN) has a Market Cap of €61.17 Mil as of Jun. 30, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on BRAIN Biotech AG and its competitors. According to the industry distribution chart, BRAIN Biotech AG ranks #1116 out of 1634 companies in the Chemicals industry, placing it in the top 68.3%.
Is BRAIN Biotech AG's Market Cap too high?
BRAIN Biotech AG's current Market Cap is €61.17 Mil. Based on the distribution chart, BRAIN Biotech AG ranks #1116 out of 1634 companies in the Chemicals industry, which is below the industry midpoint. Overall, BRAIN Biotech AG has a GF Score™ of 66/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BRAIN Biotech AG's Market Cap compare to LIN and SHW?
According to the Chemicals industry distribution chart, BRAIN Biotech AG ranks #1116 out of 1634 companies for Market Cap. This places BRAIN Biotech AG in the lower half of its industry. The industry median Market Cap is 295.54. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Chemicals company?
The median Market Cap among Chemicals companies is 295.54, based on 1,634 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on BRAIN Biotech AG and its competitors. For the Chemicals industry, the median Market Cap is 295.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BRAIN Biotech AG's current Market Cap is €61.17 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BRAIN Biotech AG stock overvalued right now?
Based on GuruFocus' analysis, BRAIN Biotech AG (HAM:BNN) is currently considered Modestly Overvalued. The stock's GF Value™ is €2.56, compared to a current price of €2.83 — trading 10.5% above its estimated fair value. The current Market Cap is €61.17 Mil. BRAIN Biotech AG's overall GF Score™ is 66/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For BRAIN Biotech AG (HAM:BNN), the current Market Cap is €61.17 Mil as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BRAIN Biotech AG (HAM:BNN) Overvalued in 2026?
Based on GuruFocus' analysis, BRAIN Biotech AG stock appears to be overvalued.
The current stock price of €2.83 is trading 10.5% above its estimated GF Value™ of €2.56.
GuruFocus considers BRAIN Biotech AG to be Modestly Overvalued.
Key valuation signals for HAM:BNN:
Market Cap: €61.17 Mil
GF Value™: €2.56 vs. price of €2.83 (10.5% above fair value)
No single metric tells the full story. See the HAM:BNN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BRAIN Biotech AG is an industrial biotechnology specialist focused on enzyme technology, microbial production strains, and bioprocess design to enable bio-based innovations. The Group conducts research, development, and production for client specifications and its own product portfolio, supporting customers in the food and beverage, chemical, and life sciences industries with solutions that enhance productivity, efficiency, and sustainability. Its operations are organized into two segments: BRAIN Biocatalysts, which develops, produces, and distributes specialty enzymes, microorganisms, and ingredients and generates the majority of revenue, and BRAIN BioIncubator, which focuses on development projects. The company operates in Germany and other countries.
66GF Score
Get the complete analysis for HAM:BNN
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:BNN has been successfully added to your 
